双示踪剂18F-FDG与68Ga-PSMA PET/CT成像评估转移性去势抵抗性前列腺癌异质性表型以预测新型激素治疗反应
本研究回顾性分析205例前列腺癌患者(23例生化复发、68例转移性去势敏感性前列腺癌、114例转移性去势抵抗性前列腺癌)的双示踪剂18F-FDG与68Ga-PSMA PET/CT显像,其中62例mCRPC患者接受新型激素治疗。患者按PSMA/FDG摄取分为PSMA+FDG-、PSMA+FDG+和PSMA-FDG+三组,评估PSMA-SUVmax与FDG-SUVmax比值(SUV ratio)对无进展生存期的预测价值。结果发现从生化复发到mCRPC阶段PSMA+FDG-患者比例下降而FDG+病例显著增加(P=0.001),PSMA-FDG+组中位PFS显著短于PSMA+FDG-组(133 vs 497天;P=0.027),PSMA+FDG+组中高SUV ratio患者中位PFS优于低SUV ratio患者(368 vs 147天;P=0.031)。
要点
- 双示踪剂PET/CT可揭示前列腺癌病灶间异质性,FDG+病例从生化复发至mCRPC阶段显著增加(P=0.001)。
- NHT队列中PSMA-FDG+组中位PFS显著短于PSMA+FDG-组(133 vs 497天;P=0.027)。
- PSMA+FDG+组中高SUV ratio患者中位PFS优于低SUV ratio患者(368 vs 147天;P=0.031)。
核心结论
- 双示踪剂成像可揭示前列腺癌病灶间异质性,SUV ratio可能有助于预测NHT的早期反应。
研究设计与样本
- 回顾性分析205例前列腺癌患者(23例生化复发、68例转移性去势敏感性前列腺癌、114例mCRPC),均接受双示踪剂18F-FDG与68Ga-PSMA PET/CT成像。
- 其中62例mCRPC患者接受NHT,按PSMA/FDG摄取分为PSMA+FDG-、PSMA+FDG+和PSMA-FDG+三组。
- 评估PSMA-SUVmax与FDG-SUVmax比值(SUV ratio)对无进展生存期(PFS)的预测价值。
主要发现
- 从生化复发到mCRPC阶段,PSMA+FDG-患者比例下降,而FDG+病例显著增加(P=0.001)。
- NHT队列中,PSMA-FDG+组(第3组)中位PFS显著短于PSMA+FDG-组(第1组)(133 vs 497天;P=0.027)。
- PSMA+FDG+组(第2组)中,高SUV ratio患者中位PFS优于低SUV ratio患者(368 vs 147天;P=0.031)。
关键数值与推荐
- PSMA+FDG-、PSMA+FDG+、PSMA-FDG+三组分类基于双示踪剂PET/CT的PSMA与FDG摄取情况。
- SUV ratio定义为PSMA-SUVmax与FDG-SUVmax的比值。
- PSMA+FDG-患者比例从生化复发至mCRPC阶段下降,FDG+病例增加(P=0.001)。
- NHT队列中PSMA-FDG+组中位PFS为133天 vs PSMA+FDG-组497天(P=0.027)。
- PSMA+FDG+组中高SUV ratio患者中位PFS为368天 vs 低SUV ratio患者147天(P=0.031)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study evaluated interlesion heterogeneity in prostate cancer using dual-tracer imaging (PSMA and FDG) and explored its predictive value for novel hormone therapy (NHT). PATIENTS AND METHODS: A total of 205 prostate cancer patients (23 biochemical recurrences, 68 metastatic castration-sensitive prostate cancers, 114 metastatic castration-resistant prostate cancers [mCRPC]) who underwent dual 18 F-FDG and 68 Ga-PSMA PET/CT imaging were retrospectively analyzed. Among them, 62 mCRPC patients received NHT. Patients were classified into 3 groups: PSMA+FDG-, PSMA+FDG+, and PSMA-FDG+. SUV ratio , the ratio of PSMA-SUV max to FDG-SUV max , was evaluated for its predictive value on progression-free survival (PFS). RESULTS: The proportion of PSMA+FDG- patients decreased from biochemical recurrence to mCRPC stages, whereas FDG+ cases increased significantly ( P = 0.001). In the NHT cohort, group 3 (PSMA-FDG+) had significantly shorter median PFS than group 1 (133 vs 497 days; P = 0.027). In group 2, patients with a high SUV ratio had better median PFS than those with a low SUV ratio (368 vs 147 days; P = 0.031). CONCLUSIONS: Dual-tracer imaging reveals interlesion heterogeneity in prostate cancer, and SUV ratio may help predict early response to NHT.
引用
- Bian L, Li P, Wang X, et al. Dual-Tracer 18 F-FDG and 68 Ga-PSMA PET/CT Imaging of Heterogeneous Phenotypes of Metastatic Castration-Resistant Prostate Cancer for Predicting Response to Novel Hormone Therapy. Clin Nucl Med. 2024. PMID: 39601077. doi:10.1097/RLU.0000000000005587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。